Australia markets closed

China SXT Pharmaceuticals, Inc. (SXTC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5322-0.0179 (-3.25%)
At close: 03:51PM EST
0.5772 +0.05 (+8.46%)
After hours: 05:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.5501
Open0.5601
Bid0.0000 x 900
Ask0.0000 x 1200
Day's range0.5303 - 0.5601
52-week range0.0900 - 2.2800
Volume73,084
Avg. volume794,813
Market cap1.43M
Beta (5Y monthly)0.68
PE ratio (TTM)N/A
EPS (TTM)-9.6470
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

    Jiangsu, China, Nov. 07, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC) announced today that on November 3, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the minimum bid price per share for its ordinary shares has been below $1.00 for a period of 30 consecutive business days and the Company therefore no longer meets the minimum b

  • GlobeNewswire

    China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split

    TAIZHOU, China, May 18, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS") announced today that an 1 for 20 reverse split of its ordinary shares

  • GlobeNewswire

    China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million

    TAIZHOU, China, March 14, 2022 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that it entered into a securities purchase agreement t